Building On Bayer
Onyx has learned a lot in its almost twenty year history with Bayer, managing through the upside and downside of having a Big Pharma partner.
You may also be interested in...
Oncology-focused pharmas and multiple myeloma players, as well as would-be MM competitors, top Wall Street’s list of possible Onyx buyers. A successful deal could aid the longstanding biotech rally that has retrenched in recent weeks.
Adding indications for Nexavar is critical to Bayer HealthCare’s plan to become a major global player in cancer therapeutics, Bayer oncology leader says at ASCO.
Regulatory filings will be based on results of the Phase III DECISION trial reported at ASCO showing a near double progression-free survival advantage compared to placebo; no further overall survival analyses will be done because of crossover.